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Background. Podocytes are terminally differentiated and
highly specialized epithelial cells. The factors governing
podocyte differentiation are poorly understood. We tested the
hypothesis that all-trans retinoic acid (ATRA), a vitamin A
derivative, induces podocyte differentiation in vitro and in vivo.
Methods. We tested the effects of ATRA on podocytes. Pri-
mary rat, primary mouse, and immortalized mouse podocytes
were exposed to ATRA (1, 5, 10, 20, 40, 50, 80, 160, and
200 lmol/L) or control (ethanol) for 72 hours. Cell morphol-
ogy was examined by electron microscopy, the expression of
podocyte specific proteins was measured by immunofloures-
cence and Western blot analysis, cell number and apoptosis were
measured by 3-[4,5] dimethylthiazol-2,5-diphenyltetrazolium
bromide (MTT) assay and Hoechst staining, respectively. To
determine if ATRA alters podocyte differentiation in vivo,
experimental injury was induced in C57BL6 mice using the
antiglomerular antibody. Animals were given either daily in-
traperitoneal ATRA (16 mg/kg) or vehicle (corn oil). For end
points, we measured proteinuria, podocyte-specific protein im-
munostaining, and proliferation [proliferating cell nuclear anti-
gen (PCNA)] at days 5 and 14 (N = 5/group/time point).
Results. ATRA induced podocyte process formation in
vitro, and significantly increased the expression of nephrin
and podocin. This coincided with a reduction in proliferation.
ATRA also significantly prevented the decrease in staining for
synaptopodin, nephrin, and podocin in experimental animals
(P < 0.05 vs. control). This was accompanied by reduced pro-
teinuria and decreased podocyte proliferation (P < 0.05 vs.
control).
Conclusion. ATRA induces podocyte differentiation in vitro
and in vivo and alters the expression of certain podocyte-specific
proteins. Further studies are ongoing to delineate the mecha-
nism of this effect.
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Podocytes, also called visceral glomerular epithelial
cells, line the glomerular capillary loops [1, 2]. They com-
prise a cell body from which major and minor processes
extend and culminate in a fine network of interdigitat-
ing foot processes. Podocytes form the final component
of the glomerular filtration barrier, and this highly spe-
cialized function requires that it maintain a differen-
tiated phenotype. During glomerulogenesis, immature,
undifferentiated and proliferating podocytes switch to
a mature, differentiated and quiescent phenotype [3].
The onset of podocyte differentiation coincides with the
expression of several podocyte-specific proteins, includ-
ing nephrin, podocin, WT-1, and synaptopodin. Recent
studies have shown that the levels of the slit diaphragm
proteins, nephrin and podocin, decrease in diseases of
podocytes, including minimal change disease, focal seg-
mental glomerulosclerosis, and diabetic nephropathy [4,
5]. It has also been well established that altered nephrin
[6, 7] and podocin [8] function, due to one or more mu-
tations, leads to altered podocyte function which is man-
ifested clinically by proteinuria.
The mechanisms governing podocyte differentiation
and proliferation are not completely understood, and the
factors that regulate nephrin and podocin expression are
only now being determined. In the current study we ex-
amined the effects of retinoic acid (RA) on podocytes.
RA is a naturally occurring derivative of vitamin A
(retinol) that binds to RA receptors [9]. The complex
formed by RA and the RA receptor then binds to DNA
at RA response elements (RARE) and causes the tran-
scription of target genes [10]. RA induces differentiation
in nonrenal epithelial cells and is used therapeutically
in acute promyelocytic leukemia to slow proliferation
and cause differentiation. RA contributes to renal mor-
phogenesis and differentiation [11]. The mechanism of
RA-induced nonrenal cell differentiation has not been
fully elucidated, but is thought to be mediated in part
through c-Myc, p21, p27, cyclin D1, and cyclin E [12–14].
Suzuki et al [15] recently showed that podocytes con-
tain three RARE in the promoter region for nephrin, a
protein expressed by the differentiated podocyte and that
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all-trans RA (ATRA) directly increased the promoter ac-
tivity of nephrin in an animal model of podocyte injury
[15]. RA has been shown to be effective in the treat-
ment of various animals models of kidney disease [16–
19]. Using a cell culture and experimental mouse model,
our data shows that ATRA induces process formation
in podocytes in vitro, enhances differentiation and lim-
its proliferation, and prevents the decrease of nephrin
and podocin protein expression in a proteinuric model of
podocyte injury in mice.
METHODS
Cell culture of rat, mouse, and heat-sensitive
mouse podocytes
Rat podocytes. Rat podocytes were established in cul-
ture as previously described [20]. In brief, differential
sieving was performed on isolated kidney cortex from
male Sprague-Dawley rats (Simonsen, Gilroy, CA, USA)
under sterile conditions. Glomeruli were collected on a
sieve with 75lm pores and placed onto culture dishes con-
taining Vitrogen (Cohesion Technologies, Palo Alto, CA,
USA). Glomeruli were cultured in K-1 media consisting
of Ham’s F-12 and Dulbecco’s modified Eagle (DME)-
low glucose 1:1 (Gibco, Grand Island, NY, USA) with 2%
NuSerum (Collaborative Biomedical Products, Bedford,
MA, USA) and insulin, transferrin, and selenium premix
(Becton Dickson Labware, Bedford, MA, USA). Follow-
ing 5 to 7 days in culture, colonies of podocytes grow-
ing out of glomeruli were excised and replated. Initially,
cells were passaged every 5 days onto Vitrogen-coated
plates in K-1 media mixed 1:1 with 3T3 cell-conditioned
media. After 20 passages, cells were plated onto plastic
in K-1 media alone. Podocytes were identified by their
polygonal shape and cobblestone appearance at conflu-
ency. The cells were also characterized as podocytes with
positive immunostaining using the following antibodies:
guinea-pig polyclonal to nephrin (GP-N2) (Research Di-
agnostics, Flanders, NJ, USA), rabbit polyclonal to WT-1
(C-19) and goat polyclonal to podocalyxin (T-19) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), rabbit poly-
clonal to podocin and rabbit polyclonal to synaptopodin
(gift from Dr. Peter Mundel, Albert Einstein College
of Medicine, Bronx, NY, USA), CD2AP (gift from Dr.
Andrey Shaw, Washington University, St. Louis, MO,
USA), sheep polyclonal to Fx1A (produced in our lab-
oratory), and mouse monoclonal to mouse cytokeratin
(BiosPacific, Emeryville, CA, USA). The cells showed
negative staining for the mesangial cell antigen Thy-
1 (OX-7 monoclonal to Thy-1) (Serotec, Raleigh, NC,
USA) and the endothelial cell antigen factor VIII (rabbit
polyclonal) (DakoCytomation California Inc., Carpinte-
ria, CA, USA) [21].
Mouse podocytes. Experiments were also performed
on podocytes derived from C57BL6 mice. Glomeruli
were sieved and prepared as previously described [20, 22].
Podocytes were grown on collagen 1 coated plates with
Roswell Park Memorial Institute (RPMI) media con-
taining 5% fetal bovine serum (FBS) (Summit biotech-
nology, Ft. Collins, CO, USA), penicillin (100 U/mL),
streptomycin (100 lg/mL), and glutamine (2 mmol/L) (all
from Irvine Scientific, Santa Ana, CA, USA) at 37◦C in
95%air/5% CO2. Podocytes were identified by previously
described criteria [20] and by confirming the presence of
podocyte-specific proteins by immunostaining for WT-1,
nephrin, podocin, and mouse monoclonal to ezrin (Ab-
cam, Inc., Cambridge, MA,USA).
Immortalized mouse podocytes. Conditionally im-
mortalized mouse podocytes, also termed heat-sensitive
mouse podocytes (HSMPs) were the third podocyte cell
type used in these studies (gift from Peter Mundel, Al-
bert Einstein College of Medicine, Bronx, NY, USA).
The methods for producing H-2Kb-tsA58 transgenic
mice and for isolating podocytes from the kidneys of these
mice have been previously described [23, 24]. These mice
are transgenic for a temperature-sensitive (tsA58) SV40
large T antigen that is under control of an interferon-
c (INF-c)-inducible promoter. Cells proliferate at 33◦C
with INF. Removal of INF and switching the growth tem-
perature to 37◦C causes podocytes to stop proliferating
and undertake a differentiated phenotype more closely
resembling that of podocytes in vivo. For these studies,
HSMPs were utilized under proliferative and undiffer-
entiated conditions in order to better demonstrate the
antiproliferative and differentiating effects of ATRA.
Exposure of podocytes to ATRA
Rat podocytes, mouse podocytes, and growth-
permissive HSMPs were plated at a concentration of
15,000cell/cm2 in standard media and allowed to adhere
overnight. Media were then removed, and replaced with
media containing ATRA (Sigma Chemical Co. St. Louis,
MO, USA) at concentrations of 0, 1, 5, 10, 20, 50, 100,
160, and 200 lmol/L for 72 hours. ATRA was suspended
in 100% ethanol to make a stock ATRA concentration
of 10 mmol/L, which was then diluted into media to the
desired concentration. For control experiments, ethanol
was diluted into standard media at similar concentrations.
All experiments were handled with minimal exposure to
ambient light or air.
Cell morphology
Cell morphology was carefully examined under light
microscopy using an inverted scope. Cellular morphology
was also examined by scanning electron microscopy on
adherent cells fixed in half-strength Karnovsky’s solution.
Immunostaining and Western blot analysis
Immunofluorescent staining of cultured cells. Follow-
ing ATRA exposure (3 days), rat podocytes and HSMPs
were washed with cold phosphate-buffered saline (PBS),
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Fig. 1. Primary culture rat and mouse podocytes stain positively for podocyte-specific proteins. (A) Rat podocytes and (B) mouse podocytes stain
positively for nephrin, podocin, and WT-1. In addition, rat podocytes stain positively for podocalyxin, CD2AP, and synaptopodin. Not shown here
are the negative staining results for all secondary and tertiary antibodies used in both cell types.
then were fixed 100% methanol at −20◦C [25]. After fix-
ation, cells were washed again with cold PBS and were
incubated with the following primary antibodies at 4◦C
overnight: rabbit polyclonal to WT-1, rabbit polyclonal to
podocin, rabbit polyclonal to synaptopodin, rabbit poly-
clonal to nephrin (gift from Harry Holthofer, Haartman
Institute, University of Helsinki, Helsinki, Finland), rab-
bit polyclonal to p35 (C-19) (Santa Cruz Biotechnology),
rabbit polyclonal to CD2AP and rabbit polyclonal to
GLEPP1 (gift from Dr. Roger Wiggins, University of
Michigan, Ann Arbor, MI, USA). After washing in PBS,
the primary antibodies were all detected using a biotiny-
lated goat antirabbit antibody (Vector, Burlingame, CA,
USA) followed by an avidin conjugated AlexaFluor 594
(Molecular Probes, Eugene, OR, USA).
Immunofluorescent staining of kidney tissue. Mouse
kidney biopsies were fixed in methyl Carnoy’s solution
or snap-frozen in liquid nitrogen for analysis of pro-
liferating cell nuclear antigen (PCNA) (mouse mono-
clonal to PCNA) (Sigma-Aldrich, St. Louis, MO, USA),
WT-1, podocin, synaptopodin, podocalyxin, and nephrin
in vivo following ATRA treatment in antiglomerular dis-
ease. Sections (4 lm) were cut from paraffin-embedded
methyl Carnoy’s fixed tissue or from 22-oxacalcitriol
(OCT)-embedded frozen tissue. Frozen sections were
then fixed in 100% methanol at −20◦C. Mouse mono-
clonal to PCNA (Beckman Coulter, Miami, FL, USA)
or rabbit polyclonal to WT-1 were incubated on methyl
Carnoy’s fixed tissue and rabbit polyclonal antibody to
podocin, nephrin, podocalyxin, and synaptopodin were
incubated on frozen sections. PCNA was incubated with
a peroxidase-conjugated rat antimouse IgM antibody
(Zymed Laboratories, Inc., South San Francisco, CA,
USA), all other primary antibodies were incubated with
biotinylayted goat antirabbit antibody followed by ei-
ther avidin D–conjugated horseradish peroxidase (WT-
1) or avidin-conjugated AlexaFluor (Molecular Probes,
Eugene, OR, USA). PCNA and WT-1 stains were visu-
alized with diaminobenzindine (DAB) (Sigma Chemical
Co.).
Double immunostaining for bromodeoxyridine
(BrdU) and podocalyxin was performed on formalin
fixed tissue. BrdU immunostaining was detected using
the cell proliferation labeling kit (Amersham Pharmacia
Biotech Inc., Piscataway, NJ, USA) using DAB as
chromogen. Following washing in PBS, antipodocalyxin
antibody (gift of Dr. Marilyn Farquhar, University of
California, San Diego, CA) was applied and the slides
incubated overnight at 4◦C. Binding of this antibody
was detected using a biotinylated anti-rabbit IgG sec-
ondary (Vector), followed by streptavidin-conjugated
AlexaFluor 594 (Molecular Probes).
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Fig. 2. All-trans retinoic acid (ATRA) reduces podocyte prolifera-
tion in vitro. (A) Cell activity of primary culture rat podocytes ex-
posed to increasing concentrations of ATRA, as measured by the 3-
[4,5] dimethylthiazol-2,5-diphenyltetrazolium bromide (MTT) assay.
(B) Cell activity of primary culture mouse podocytes exposed to ATRA.
There was a progressive decrease in MTT absorbance with increasing
ATRA concentrations. This was not due to increased apoptosis.
Western blot analysis. Western blots were performed
as previously described [25–27]. Briefly, cellular pro-
tein was extracted from cultured podocytes using TG
buffer containing 1% Triton, 10% glycerol, 20 mmol/L
Hepes, and 100 mmol/L NaCl (Sigma Chemical Co.)
with complete protease/phosphatase inhibitors (Roche
Pharmaceuticals, Nutley, NJ, USA). Protein extracts
(10 lg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
were transferred to polyvinylidine difluoride (PVDF)
membranes (PerkinElmer Life Sciences, Inc., Boston,
MA, USA). Membranes were blocked with 5% nonfat
dried milk in Tris-buffered saline Tween 20 (TBST) and
immunostained with antibodies to nephrin and podocin.
To ensure equal protein loading, all Western blots were
also exposed to antibodies to tubulin. Specific bands
were visualized using 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium (Sigma Chemical Co.).
Measuring cell proliferation: 3-[4,5] dimethylthiazol-2,5-
diphenyltetrazolium bromide (MTT) assay
Podocyte activity was assessed by MTT assay
(Promega, Madison, WI, USA) according to the instruc-
tions by the manufacturer. This assay is a nonradioactive
cell proliferation assay that identifies living cells, and is
based on the cellular conversion of a tetrazolium salt into
a formazan product, a chromophore, which can be quan-
tified by spectrophotometry. Briefly, cells were plated
into a 96-well plate, allowed to adhere overnight, and
then an appropriate concentration of ATRA was added.
Podocytes were exposed to ATRA for 3 to 5 days (rat
podocytes or heat-sensitive mouse podocytes) or 7 days
(mouse podocytes). A labeling dye included in the kit was
added 4 hours prior to the end point. A stop solution was
added to each well to stop the reaction and solubilized
the cells and the absorbance was read at 570 nm.
Measuring apoptosis: Hoechst 33342 staining
To ensure that the antiproliferative effects of ATRA
were not confounded by podocyte apoptosis in podocytes
or binucleated cells, Hoechst 33342 (Molecular Probes)
staining was performed as previously reported [28].
Careful morphologic analysis was performed and the per-
centage of apoptotic cells was quantified in adherent and
nonadherent cells using inverted fluorescent microscopy
as previously described [28, 29].
In vivo studies: Antiglomerular model
An antibody-mediated model of podocyte injury was
induced in C57BL6 mice with a sheep antiglomeru-
lar antibody (two doses of 0.3 mL/20 g body weight)
over 2 consecutive days [30, 31]. After the induction of
the antiglomerular model but before the development
of proteinuria, mice were divided into an experimental
group that received daily injections of ATRA 16.6 mg/kg
(intraperitoneally), and a control group that received
vehicle (corn oil). Experimental and control animals
were studied on day 7 and 14 (N = 5 per group/time
point). At each time point, the podocyte-specific proteins
(WT-1, nephrin, podocin, synaptopodin, and CD2AP)
and a marker for proliferation (PCNA) were measured
by immunostaining. In order to verify that the prolifer-
ating cells in this model were podocytes, we performed
double staining with BrdU and podocalyxin.
Renal function assessment. Control and experimental
mice were placed in metabolic urine collection cages in
order to obtain a timed collection for urinalysis. Urine
was analyzed for protein content utilizing the sulphos-
alicylic acid method as previously described [32]. Serum
was also collected from mice in order to evaluate blood
urea nitrogen (BUN) levels. The BUN kit (Sigma Chem-
ical Co.) is based on the direct interaction of urea with
diacetyl monomoxime to produce ammonia, which is
subsequently measured colorimetrically. The absorbance
obtained from serum samples is compared with a stan-
dard curve of increasing concentrations of urea nitrogen
standards.
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Fig. 3. All-trans retinoic acid (ATRA) induces processes in cultured podocytes. Cell morphology was assessed by scanning electron microscopy in
cultured rat podocytes. There was an increase in number and length of processes in cells exposed to ATRA, with cells taking on a typical arborized
phenotype.
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Fig. 4. All-trans retinoic acid (ATRA) increases nephrin immunostaining in cultured podocytes. Typical immunostaining for nephrin is shown
in cultured rat (A) and heat-sensitive mouse podocyte (HSMPs) (C). The intensity of immunostaining was increased in rat (B) and mouse (D)
podocytes exposed to 10 and 200 lmol/L ATRA, respectively, for 72 hours.
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Fig. 5. All-trans retinoic acid (ATRA) increases podocin immunostaining in cultured podocytes. Typical immunostaining for podocin is shown
in cultured rat (A) and heat-sensitive mouse podocytes (HSMPs) (C). The intensity of immunostaining was increased in rat (B) and mouse (D)
podocytes exposed to 10 and 200 lmol/L ATRA, respectively, for 72 hours.
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Fig. 6. Western blot analysis. Protein was extracted from control pri-
mary culture mouse podocytes (no ATRA, lane 1) and cells exposed
to 1 lmol/L (lane 2) and 5 lmol/L (lane 3) ATRA. Similar to the im-
munostaining results, the protein levels for nephrin increased in cells
exposed to both concentrations of ATRA. Tubulin was used to ensure
equal protein loading.
RESULTS
ATRA reduces podocyte proliferation in vitro
To study the effects of ATRA on podocyte prolifer-
ation, we examined three different cell lines in vitro:
rat podocytes, mouse podocytes, and HSMPs grown in
growth-permissive conditions. Although we have previ-
ously reported the use of the primary rat and mouse
podocytes, in the current study we took advantage of
the newer reagents available, and further character-
ized these cells as podocytes using the podocyte-specific
antigens (Fig. 1). The HSMPs have been previously
characterized [24, 33, 34]. As seen in Figure 1, both
the primary nonimmortalized rat and mouse podocytes
stained positively for nephrin, podocin, and WT-1. In ad-
dition, the rat podocytes stained positively for podoca-
lyxin, CD2AP, and synaptopodin and the primary culture
mouse podocytes stained positively for ezrin. In contrast,
immunostaining for Thy1, a-SMA, and factor VIII were
negative (results not shown). Taken together, these re-
sults demonstrate that these primary culture mouse and
rat cells are podocytes.
When grown in culture, all three cell types are un-
differentiated and proliferate. Viable cell number was
measured by MTT assay. Figure 2A shows that ATRA
reduced rat podocyte cell number in a concentration-
dependent fashion. Beginning at 1 lmol/L, ATRA sig-
nificantly reduced MTT absorbance compared to control
cells (P < 0.001). Similarly, ATRA significantly reduced
MTT absorbance of primary mouse podocytes (Fig. 2B)
and HSMPs grown under growth-permissive conditions
(results not shown) although at higher concentrations of
ATRA than were required with the rat podocytes.
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Fig. 7. All-trans retinoic acid (ATRA) reduces proteinuria in experi-
mental glomerular disease. Podocyte injury was induced in mice with
an antiglomerular antibody, and proteinuria was measured in control
(vehicle-treated) and experimental (ATRA-treated) animals at days 7
and 14. There was a significant increase in proteinuria in control mice
with disease. ATRA significantly reduced proteinuria at days 7 and 14
in experimental mice with disease.
To ensure that the decrease in cell number measured
by the MTT assay was not due to a loss of cells by apop-
tosis or due to an increase in the number of binucleated
cells, we performed Hoechst staining. Our results showed
that at the concentrations of ATRA used in these ex-
periments, there was a statistically insignificant number
of cells undergoing apoptosis (<4% of total cells) (P <
0.05). Moreover, less than 2% of cells were binucleated
(results not shown). Taken together, these results demon-
strated that the decrease in MTT absorbance was due to
an antiproliferative effect of ATRA on the podocytes.
ATRA induces process formation in cultured podocytes
Electron microscopy was performed to determine the
effect of ATRA on podocyte morphology, and the results
are shown in Figure 3. Exposing cultured rat podocytes
to 1 lmol/L ATRA resulted in the presence of processes,
which extended from the cell body. Ten micromoles per
liter ATRA caused a marked increase in the number and
length of processes. Similar results were obtained in cul-
tured HSMPs (results not shown).
ATRA increases the levels of nephrin and podocin
in vitro
Both rat and HSMPs were utilized to determine if
ATRA altered the expression of nephrin and podocin.
Note that the concentration of ATRA required to reduce
proliferation in rat podocytes was lower than concentra-
tions required by HSMPs to achieve the same end point.
Figure 4 shows that when undifferentiated and prolifer-
ating rat podocytes were exposed to 10 lmol/L ATRA
and when HSMPs were exposed to 200 lmol/L ATRA,
nephrin immunostaining increased compared to control
cells exposed to vehicle. Although not shown here, simi-
lar but less pronounced immunostaining for nephrin was
seen at lower concentrations of ATRA for both cells types
suggesting a dose-dependent effect of the ATRA.
Similarly, Figure 5 shows increased immunostaining
for podocin in cultured rat podocytes given 10 lmol/L
ATRA and in HSMPs given 200 lmol/L ATRA com-
pared to control. Western blot analysis was used to con-
firm these findings in primary mouse podocytes, and the
results are shown in Figure 6. ATRA at 1 lmol/L and
5 lmol/L increased the protein levels for nephrin in the
primary mouse cultures. Taken together, these results
show that ATRA increased the protein levels for nephrin
and podocin in cultured podocytes in a concentration-
dependent fashion, and this coincided with a decrease in
proliferation.
Proteinuria is reduced in experimental glomerular
disease by ATRA
Pilot studies were performed to determine if giving 16
mg/kg intraperitoneally for 7 days caused side effects in
normal mice. Our results showed that there was no weight
loss, ruffled fur, withdrawal, or diarrhea when adminis-
tered to mice at this concentration. To determine the ef-
fect of ATRA on podocytes in vivo, were injected with
an antiglomerular antibody on 2 consecutive days, and
then were treated with daily intraperitoneal injections of
ATRA or vehicle (corn oil).
Figure 7 shows that compared to normal mice (white
bar), proteinuria increased significantly in the mice given
the antiglomerular antibody plus vehicle on day 7 (gray
bars) (P < 0.001 vs. normal) and day 14 (P < 0.001 vs.
normal). ATRA significantly reduced proteinuria in mice
given the antiglomerular antibody (black bars) at day 7
(P < 0.001 vs. control) and day 14 (P < 0.001 vs. control).
BUN increased in control rats at days 7 (P < 0.01 vs. nor-
mal) and 14 (P < 0.01 vs. normal), but this was not altered
by the administration of ATRA (results not shown). To
ensure that the effects of ATRA did not result from a
change in the binding of the antiglomerular antibody, we
administered ATRA after the antiglomerular antibody
was given. We also performed immunostaining for the
antiglomerular antibody, which showed that there was
no difference in the antibody binding between the con-
trol animals and those that were given ATRA as shown
in Figure 8.
ATRA prevented a decrease in nephrin and podocin
in nephritic mice
Figure 9 shows immunostaining for the slit di-
aphragm proteins, synaptopodin, podocin, and nephrin in
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Fig. 8. All-trans retinoic acid (ATRA) does not affect the binding of the antiglomerular antibody. To ensure that the effects of ATRA on the animal
model were not due to a decrease in the binding of the antiglomerular antibody, we stained for the sheep IgG at day 7 after antibody administration.
We did not find any difference in the staining intensity between the control mice (A) and ATRA-treated mice (B), which indicates that ATRA did
not alter the binding of the antiglomerular antibody.
Synaptopodin
Control ATRA
Podocin
Nephrin
Normal mouse Antiglomerular model D14
Fig. 9. All-trans retinoic acid (ATRA)
prevents the decrease in immunostaining
podocyte-specific proteins in experimental
glomerular disease. The typical pattern of
indirect immunoflourescent immunostaining
for synaptopodin (synpo), podocin, and
nephrin is shown in normal mice (column 1).
Column 2 shows that podocyte injury in the
antiglomerular antibody model at day 14 was
associated with a decrease in immunostaining
for synaptopodin, podocin, and nephrin.
As shown in column 3, ATRA ameliorated
the decrease in staining for synaptopodin,
nephrin, and podocin. We also tested for p35
and CD2AP and found that ATRA partially
prevented the decrease in staining p35 but
not CD2AP.
normal, control, and experimental mice on day 14 af-
ter disease induction. Experimental glomerular disease
caused a decrease in immunostaining for synaptopodin,
podocin, nephrin, p35, and CD2AP in control nephritic
mice given vehicle. In contrast, ATRA prevented the de-
crease in immunostaining for synaptopodin, podocin, and
nephrin in the experimental group of nephritic mice (Fig.
9). The effects of ATRA on p35 and CD2AP were not dif-
ferent from control nephritic animals given vehicle (re-
sults not shown). Taken together, in this model, ATRA
treatment prevented the decrease in immunostaining of
the slit diaphragm proteins nephrin and podocin, and also
the actin-binding proteins, synaptopodin, with a concomi-
tant reduction in proteinuria.
Podocyte proliferation and differentiation are altered by
ATRA in experimental glomerular disease
We have previously shown that giving the antiglomeru-
lar antibody to mice causes podocyte dedifferentia-
tion and increased proliferation [30]. Immunostaining
for PCNA was used as a marker for DNA synthesis.
Figure 10 shows the number of PCNA-positive cells in
the ATRA-treated and control groups at days 7 and
14. PCNA staining was significantly increased at day 7
(P < 0.05 vs. normal) and day 14 (P < 0.05 vs. normal) in
control mice given the antiglomerular antibody and ve-
hicle. ATRA did not have a statistically significant effect
on PCNA staining on day 7. In contrast, ATRA signifi-
cantly reduced podocyte proliferation in nephritic mice
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Fig. 10. All-trans retinoic acid (ATRA) alters podocyte proliferation
in experimental glomerular disease. Podocyte proliferation was mea-
sured by immunostaining for proliferating cell nuclear antigen (PCNA)
in control and experimental mice. The number of cells that stained pos-
itive for PCNA increased in control and experimental mice at day 7
(P < 0.05 vs. normal). PCNA staining increased further at day 14 in
control mice (P < 0.05 vs. normal). ATRA significantly reduced PCNA
immunostaining in experimental mice at day 14 (P < 0.05 vs. control).
at day 14 (P < 0.05 vs. control). Previous studies from our
group have shown that the podocytes proliferate in the
antiglomerular model and that there is minimal cellular
infiltration [31]. To verify that the PCNA-positive cells
were podocytes, we performed double staining for BrdU
and podocalyxin (Fig. 11). BrdU labels cells undergo-
ing DNA synthesis and podocalyxin was used to identify
podocytes because it has been found to be positive even
in dedifferentiated podocytes [35]. As shown in Figure 10,
the BrdU-positive cell was also positive for the podocyte
antigen podocalyxin. Taken together, these results show
that ATRA reduced DNA synthesis in podocytes in ex-
perimental glomerular disease.
We [30, 36] and others [37] have previously shown that
podocytes dedifferentiate in order to proliferate. Previ-
ous studies have shown that WT-1 staining is specifically
increased in differentiated podocytes [38]. To determine
if the decrease in podocyte proliferation by ATRA was
due to the prevention of podocyte dedifferentiation, we
performed WT-1 staining in control and experimental
mice, and the results are shown in Figure 9. Quantification
showed a significant decrease in WT-1 staining in control
mice compared to normal at day 7 (P < 0.001) and day
14 (P < 0.001). In contrast, giving ATRA to nephritic
mice prevented the decrease in WT-1 staining at day 7
(P < 0.001 vs. control) and day 14 (P < 0.001 vs. control)
of nephritis. The density of WT-1 staining could have been
affected by infiltrating cells or crescent formation. In this
experiment, we controlled for the effect of crescent for-
mation by using a lower dose of the antiglomerular an-
tibody such that crescents were not found even in the
control animals. Taken together, these data substantiate
the antiproliferative effects of ATRA on the podocyte in
this disease model.
DISCUSSION
For the podocyte to maintain its normal function,
this highly specialized cell must be fully differentiated
and quiescent. Podocyte dedifferentiation and prolifer-
ation characterize certain renal diseases, such as cel-
lular/collapsing focal segmental glomerulosclerosis [39],
and more recently it has also been shown that podocytes
proliferate as part of the crescent in antiglomerular base-
ment membrane disease [40]. The onset of podocyte dif-
ferentiation during development coincides with the de
novo expression of nephrin [41] and podocin [8, 42].
Several sporadic proteinuric diseases of the kidney cor-
relate with a decrease in nephrin and podocin levels [8,
43, 44]. Factors or molecules which regulate podocyte
differentiation are not well elucidated, and the regula-
tion of the slit diaphragm proteins, nephrin and podocin,
remain to be determined. In this study we focused on
ATRA because previous studies have shown that ATRA
induces differentiation in nonrenal epithelial cells, and
enhances the promoter activity of nephrin [15]. In the
current study we showed ATRA induced process forma-
tion in cultured podocytes, maintained a differentiated
phenotype, and also reduced podocyte proliferation in
vitro. In an experimental glomerulonephritis model, we
showed that ATRA altered the protein levels for nephrin
and podocin, reduced podocyte proliferation, maintained
podocyte differentiation, and diminished proteinuria.
The first major finding in the current study was that
ATRA had a marked effect on podocyte phenotype and
state of differentiation in vitro and in vivo. The differen-
tiated podocyte phenotype is characterized by the pres-
ence of major, minor, and interdigitating foot processes.
When grown in culture, these cells dedifferentiate, lose
their processes, and form a “cobblestone” pattern. In the
current study, when cultured nonimmortalized rat and
undifferentiated immortalized HSMPs were exposed to
ATRA, there was a marked induction of arborization and
process formation in both cell types.
In its differentiated state, the podocyte expresses
certain proteins such as WT-1, nephrin, and podocin.
When grown in culture, podocytes have decreased ex-
pression of such podocyte specific proteins and the
loss of the expression of these proteins correlates with
dedifferentiated phenotype. Nephrin and podocin are
critical slit diaphragm proteins, and podocin augments
nephrin signaling [45]. Mutations in nephrin and podocin
cause proteinuria in congenital, hereditary, and sporadic
glomerulopathies. The reduced expression of nephrin
and podocin correlate with proteinuria in diabetic and
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Fig. 11. Podocytes proliferate in the
antiglomerular model. To verify that the
proliferative cells in our in vivo model were
podocytes, we performed staining for the
podocyte specific protein podocalyxin (A)
and bromodeoxyuridine (BrdU) (B) as a
marker of DNA synthesis at day 5 after
disease induction in a control animal. (C)
These images were merged to confirm that
the proliferative cells within this model are
podocytes.
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Fig. 12. WT-1 immunostaining. Podocyte number was evaluated quan-
titating the number of cells expressing WT-1. Podocyte number de-
creased in control animals with antiglomerular antibody disease given
vehicle at days 7 and 14. All-trans retinoic acid (ATRA) prevented the
decrease in podocyte number at both time points.
nondiabetic diseases [46]. In the current study, ATRA
treatment correlated with an increased expression of pro-
teins of podocyte differentiation in vitro. These pheno-
typic and podocyte-specific protein changes consistent
with the differentiated podocyte phenotype, occurred
within 72 hours of exposure to ATRA, and were dose-
dependent.
In the current in vivo study, we demonstrated that the
effect of ATRA on podocyte differentiation was also rel-
evant in disease. The antiglomerular antibody model is
typified by proteinuria, podocyte dedifferentiation [30],
and decreased expression of podocyte-specific proteins.
Clinically, podocyte dedifferentiation characterizes col-
lapsing glomerulopathy [47], and correlates closely with
disease severity. In this animal model, we demonstrated
that in contrast to control animals, ATRA prevented the
decrease in WT-1, nephrin, podocin, and synaptopodin
levels. These morphologic and immunohistochemical
markers of podocyte differentiation in the ATRA-treated
animals correlated with statistically significant less pro-
teinuria compared to controls.
The second major finding was that ATRA reduced
podocyte proliferation in vitro and in vivo. Prolifera-
tion occurs in podocytes during glomerulogenesis, but
is absent in mature podocytes [3]. However, cell cycle
entry occurs again in immune and nonimmune-mediated
podocyte diseases [48]. In the experimental antiglomeru-
lar antibody mouse model (used in this study) [30, 49]
and collapsing glomerulopathy [36, 47], podocytes pro-
liferate. Studies have shown that the proliferation of
podocytes in certain diseases may be due to changes
in specific cyclin-dependent kinase inhibitors [36].
Gherardi et al [50] have shown that inhibiting the activ-
ity of cyclin-dependent kinases reduces podocyte prolif-
eration in experimental human immunodeficiency virus
(HIV)-associated nephropathy (HIVAN), and this is
accompanied by a decrease in glomerulosclerosis. The
Vaughan et al: Podocytes and ATRA 143
current study shows that we can add ATRA to the
list of potential inhibitors of podocyte proliferation.
ATRA induced differentiation and was antiproliferative
in podocytes in vitro and in vivo.
Further studies are needed to investigate the mecha-
nisms by which ATRA causes podocyte differentiation
and decreases proliferation. ATRA has been studied pri-
marily in nonrenal cells and has been shown to medi-
ate its effects through G0/G1 or G1/S phase arrest but
the mechanism has not been fully elucidated [51]. In hu-
man myeloid cell lines, ATRA induced cell cycle arrest
is accompanied by a decrease in c-Myc and cyclin E with
an up-regulation of p27kip1 [13] and p21 [49]. In human
mammary epithelial cells, the cell cycle arrest is associ-
ated with a decrease in cyclin D1 and is independent of
p53 [14, 52]. In human squamous carcinoma cells, RA
arrest correlates with induction of p27kip1 and inhibition
of cyclin-dependent kinase 3 [12]. Finally, ATRA has an
antiapoptotic effect by inhibition of hydrogen peroxide
(H2O2)-induced apoptosis through the c-Jun N-terminal
kinase (JNK)-activator protein 1 (AP-1) pathway [53].
In the kidney, preliminary studies have suggested po-
tential important pathways for the RAs. ATRA has
been recently shown by Suzuki et al [15] to increase
the promoter activity of nephrin, but nothing has been
reported on the effect of ATRA on podocin [19]. Fur-
ther studies are needed to determine if ATRA alters
podocin levels via transcriptional and/or translational
mechanisms. Wagner et al [54] showed that ATRA re-
duced glomerulosclerosis in the Thy1 model of mesan-
gial proliferative glomerulonephritis. Finally, Bek et al
[55] have provided an interesting potential mechanism
by which RA could protect podocytes in disease states.
They demonstrated that Stra13, a known RA-inducible
gene, reduced nicotinamide adenine dinucleotide phos-
phate (NADPH)-dependent superoxide generation in
podocytes, and was protective against oxidative stress.
Although all of these are potential mechanisms for the
effects of ATRA on the podocyte in disease states, the
actual effects are likely multifactorial and need contin-
ued investigation.
CONCLUSION
The results of the current study show that ATRA
has profound effects on podocytes in vitro and in vivo.
ATRA induces process formation and differentiation,
limits proliferation, and alters the expression of nephrin
and podocin. Due to the impressive protective effects of
ATRA on podocytes in the current and recent studies, we
propose that more research is needed to investigate the
mechanism(s) for the effects of RA on the podocyte. In
addition, clinical studies need to be undertaken to inves-
tigate ATRA as a potential future therapy for patients
with podocyte disease.
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